ALISO VIEJO, Calif., Feb. 17, 2011 /PRNewswire/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced the promotion of Gregory J. Flesher to the position of Senior Vice President of Corporate Development and Chief Business Officer. In this role, Mr. Flesher will oversee corporate strategy, business development, program management, and business operations.
"Greg has shown exceptional leadership over the past several years and has played a key role in the transformation of AVANIR into a commercial-stage organization," said Keith Katkin, President and Chief Executive Officer. "His broad pharmaceutical background in business development, sales and marketing, and research and development provides a strong foundation which will help AVANIR grow into a successful CNS company. I look forward to Greg's continued contributions to the executive management team."
Mr. Flesher has over 16 years of experience in the pharmaceutical industry. He was previously Vice President of Business Development for AVANIR, with responsibility for business transactions, intellectual property, and NUEDEXTA™ lifecycle planning. Prior to joining the Company, he held various positions of increasing responsibility at InterMune Inc., Amgen Inc., and Eli Lilly and Company.
Mr. Flesher graduated from Purdue University with a degree in Biology and has completed his doctorate coursework in Biochemistry and Molecular Biology at Indiana University School of Medicine.
About AVANIR Pharmaceuticals, Inc.
AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about AVANIR, please visit www.avanir.com.
AVANIR™ and NUEDEXTA™ are trademarks owned by AVANIR Pharmaceuticals, Inc.
©2011 AVANIR Pharmaceuticals, Inc. All Rights Reserved.
|SOURCE AVANIR Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved